The Curative Efficiency of Lamivudine Plus Adefovir Dipivoxil Combination in HBeAg-Negative Chronic Hepatitis B Patients

Objective:To observe the curative efficacy and safety of lamivudine combined with adefovir dipivoxil on HBeAg-negative initial treated chronic hepatitis B (CHB) patients.Methods:Outatients from our hospital between June,2006 and August,2007,who received lamivudine 100 mg and adefovir dipivoxil 10 mg per day were screened.And the level of ALT,HBV DNA,and urea nitrogen,as well as the statue of HBsAg and anti-HBs were detected at week 12,24,and 48.Results:The undetectable rates of HBV DNA were 17%,43%,and 87% at week 12,24,and 48 respectively,and the difference in response rate were statistic significantly (P0.05).The ALT normalization rate were 13%,67%,and 100% at week 12,24,and 48 respectively,and the difference in response rate were statistic significantly (P0.05);During the course of antiviral therapy,the loss of HBsAg was not observed and all patients were well tolerated.Conclusion:The combination of lamivudine and adefovir dipivoxil were effective for HBeAg-negative CHB patients,and this treatment strategy provided us a new option in clinical antiviral practice.